• PepGen priced a public offering of 25,000,000 common shares at $5 per share.
• Gross proceeds are expected to total $125 million before underwriting discounts, commissions and offering expenses.
• Underwriters have a 30-day option to purchase up to 3,750,000 additional common shares at the offering price, less underwriting discounts and commissions.
• The offering is expected to close on or about November 13, 2026, subject to customary closing conditions.
• Net proceeds will fund ongoing clinical development of its product candidate, working capital and other general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PepGen Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261111287359) on November 12, 2026, and is solely responsible for the information contained therein.